

10 December 2019

Completion of First Subscription

- Shares allotted for First Subscription raising \$2.4m at 0.5 cents per share
- A Second Subscription to be completed to raise a further \$6,888,986 at \$0.01
- Bill Fry appointed Managing Director, Ben Rohr to Chief Operating Officer

EVE Investments (ASX:EVE), an ASX listed health, nutrition and wellness company, announces Everhoney Biotech Australia Pty Ltd (“Everhoney”) and Hong Kong Jusheng Bolang Technology Co., Limited (“Jusheng Bolang”) have completed their First Subscription under their respective Subscription Deeds.

The First Subscription raised \$2,411,145 at \$0.005, a Second Subscription will be issued within 3 months of the execution of the Subscription Deeds and raise a further \$6,888,986 at \$0.01. Both subscriptions were overwhelmingly approved at the Company’s recent Annual General Meeting. AGC Capital, a Sydney-based financial services firm, which specialises in advising on IPOs, funds management and corporate finance activities acted as EVE’s advisor to the subscription.

Board Appointment

As per its entitlement under its Subscription Deed, Everhoney has appointed a nominee director to the Company’s Board, Mr Carlos Jin. Mr Jin is a director of Everhoney and has nearly 30 years of working experience in foreign companies as well as Chinese state-owned enterprises, specifically in the functions of human resources management and investment management and holds a master’s degree in business administration.

Executive Changes

The Board has agreed the following changes to the executive function of the Company effective today:

- Mr Gregory Fry has been elevated from Executive Director to Managing Director/CEO.
- Mr Ben Rohr has been appointed Chief Operating Officer.

The details of Mr Fry’s contract are appended to this announcement.

For more information:

Bill Fry
Managing Director
Eve Investments Ltd
+61 8 6465 5500
billf@eveinvestments.com.au

About EVE Investments

EVE Investments invests in companies with a focus on the medical nutrition and wellness sector. The Company’s investment strategy has a three pronged approach.

1. To invest in businesses that are in the early growth phase with the aim to support their expansion programs.
2. To identify products that have unique medicinal properties and a global reach application.
3. Preference for natural organic products that have demonstrated medicinal benefits.

For further information, please visit www.eveinvestments.com.au and follow us on Twitter [@EVEInvestments](https://twitter.com/EVEInvestments)

Appendix 1 - Material Terms of Managing Director Agreement

Commencement Date	10 December 2019
Term	On-going basis
Fixed Remuneration	\$328,500 including superannuation entitlements
Termination and Notice	The Company or Mr Fry may terminate the agreement by providing 3 months' notice. The Company may elect at its discretion to make payment in lieu of notice.